# US 2012/0251632 A1 · Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251632 A1
- Document ID: US20120251632A1
- Status: Published application
- Kind: A1
- Application number: 13/525,181
- Filed: 2012-06-15
- Published: 2012-10-04
- Earliest claimed: 2009-11-18
- Assignees: MediciNova, Inc.
- Inventors: Kazuko MATSUDA; Yuichi Iwaki; Kirk W. Johnson
- Web page: https://patentgrep.com/patent/US20120251632A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/24: having an amino or nitro group
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/16: Central respiratory analeptics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.

## Claims

### Claim 1

A method of improving one or more clinical outcomes of an individual experiencing an acute exacerbation of asthma, comprising administering to an individual suffering from an acute exacerbation of asthma an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.

### Claim 2 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof is administered after administration of the SOC treatment regimen.

### Claim 3 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof is administered contemporaneously with the SOC treatment regimen.

### Claim 4 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof s administered before administration of the SOC treatment regimen.

### Claim 5 (depends on 1)

The method of claim 1 in which the SOC treatment regimen comprises administration of one or more β-agonist bronchodilators, one or more anti-cholinergic drugs, one or more corticosteroids, or combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1 in which the SOC treatment regimen includes the administration of magnesium.

### Claim 7 (depends on 5)

The method of claim 5 in which the one or more β-agonist bronchodilators, or one or more anti-cholinergic drugs are administered by inhalation, injection, or intravenous infusion.

### Claim 8 (depends on 5)

The method of claim 5 in which the one or more β-agonist bronchodilators are selected from albuterol, bitolterol, levalbuterol, pirbuterol, epinephrine, terbutaline, formoterol and salmeterol.

### Claim 9 (depends on 5)

The method of claim 5 in which the one or more anti-cholinergic drugs are selected from ipratropium and tiotropium.

### Claim 10 (depends on 5)

The method of claim 5 in which the one or more corticosteroids are selected from prednisone, methylprednisolone and prednisolone.

### Claim 11 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof is administered intravenously.

### Claim 12 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof is administered orally.

### Claim 13 (depends on 1)

The method of claim 1 in which the bedoradrine or a pharmaceutically acceptable salt thereof is administered by inhalation.

### Claim 14 (depends on 1)

The method of claim 1 in which the amount of bedoradrine or a pharmaceutically acceptable salt thereof administered to the individual falls in the range of 100 to 5,000 μg.

### Claim 15 (depends on 14)

The method of claim 14 in which about 500 to about 1,500 μg of bedoradrine or a pharmaceutically acceptable salt thereof is administered intravenously over a period of about 5 to about 120 minutes.

### Claim 16 (depends on 1)

The method of claim 1 in which the patient has been admitted to an emergency room.

### Claim 17 (depends on 1)

The method of claim 1 in which the one or more clinical outcomes improved is selected from an increase in FEV1, a reduction in likelihood of hospitalization, an improvement in dyspnea scores, a reduction in incidence of intubation, a reduction in length of stay in an intensive care unit and an improvement in self-ambulation unaccompanied by respiratory distress.

### Claim 18 (depends on 17)

The method of claim 17 in which FEV1 improves by 5% or more, 10% or more, or 15% or more.

### Claim 19 (depends on 17)

The method of claim 17 in which the likelihood of hospitalization of the individual receiving the combination treatment is reduced compared with an individual receiving only the SOC treatment regimen.

### Claim 20 (depends on 19)

The method of claim 19 in which the likelihood of hospitalization of the individual receiving the combination treatment is reduced to about 25% or less, about 20% or less, or about 15% or less.

### Claim 21 (depends on 1)

The method of claim 1 in which the individual is not responsive to an inhaled β-agonist bronchodilator.

### Claim 22 (depends on 21)

The method of claim 21 in which the inhaled β-agonist bronchodilator is albuterol.

### Claim 23 (depends on 1)

The method of claim 1 in which the individual experiences improvement from the acute exacerbation of asthma for about 1 hour or more, about 2 hours or more, about 3 hours or more, about 4 hours or more, about 5 hours or more, about 6 hours or more, or about 8 hours or more after the combination treatment.

### Claim 24 (depends on 1)

The method of claim 1 in which the individual experiences improvement in FEV1 (L), FEV1 (% predicted), PEFR, arterial blood oxygen saturation, respiratory rate, or combinations thereof after the combination treatment, unaccompanied by one or more clinically observable adverse events.

### Claim 25 (depends on 24)

The method of claim 24 in which the one or more clinically observable adverse events is selected from an increased heart rate, an increased blood glucose, tremor, headache, palpitations and a jittery feeling.

### Claim 26

A method of alleviating one or more negative effects of an acute exacerbation of asthma, comprising administering to a patient, who has been diagnosed as suffering from an acute exacerbation of asthma, an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The method of claim 26 in which the bedoradrine is administered intravenously, orally, or by inhalation.

### Claim 28 (depends on 27)

The method of claim 27 in which the patient fails to respond to the SOC treatment regimen.

### Claim 29 (depends on 27)

The method of claim 27 in which the patient experiences improved FEV1 relative to the patient's pre-treatment FEV1 and the improved FEV1 persists on average for at least about 6 hours at a level that is about 50% or more of a peak effect.

### Claim 30 (depends on 27)

The method of claim 27 in which the daily amount of bedoradrine or a pharmaceutically acceptable salt thereof administered to the patient falls in the range of about 300 to 1500 μg.
